63 results
424B5
ITCI
Intra-Cellular Therapies Inc
18 Apr 24
Prospectus supplement for primary offering
5:23pm
secondary endpoint in the study by demonstrating a statistically significant and clinically meaningful reduction in the clinician’s assessment
8-K
EX-99.2
ITCI
Intra-Cellular Therapies Inc
16 Apr 24
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:40pm
in the clinician’s assessment of improvement in the overall severity on the CGI-S score compared to placebo at Week 6 in the combined patient population of MDD
424B5
ITCI
Intra-Cellular Therapies Inc
16 Apr 24
Prospectus supplement for primary offering
4:37pm
by demonstrating a statistically significant and clinically meaningful reduction in the clinician’s assessment of improvement in the overall severity on the CGI
S-3ASR
EX-4.11
36bqolc
16 Apr 24
Automatic shelf registration
4:01pm
S-3ASR
EX-4.10
g9nlcbt7
16 Apr 24
Automatic shelf registration
4:01pm
8-K
EX-99.1
yj94fjv qcia00m
4 May 23
Intra-cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:37am